24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

Key Takeaways Explain This Topic AI

Hypercalcemic crisis (total calcium >=14.0 mg/dL or ionized Ca >3.0 mmol/L) presents with marked dehydration, altered mental status, and a shortened QT interval; primary hyperparathyroidism and malignancy account for >90% of all cases.

The cornerstone of hypercalcemic crisis management is aggressive volume expansion with 0.9% Normal Saline (1-2 L initial bolus, then 200-500 mL/h) combined with salmon calcitonin (rapid bridge, onset 2-4 hours, 48-hour tachyphylaxis) and intravenous zoledronic acid (4 mg over 15 min; nadir 4-7 days); loop diuretics are contraindicated until volume is fully restored.

Denosumab (monoclonal antibody against RANKL) is the therapy of choice for hypercalcemia of malignancy in patients with severe renal impairment (GFR <30 mL/min) or bisphosphonate-refractory disease.

Acute severe hypocalcemia (ionized Ca <1.1 mmol/L) manifests with neuromuscular tetany, Chvostek and Trousseau signs, and prolonged QTc; emergency management requires IV Calcium Gluconate 10% (1-2 g in 50 mL D5W over 10-20 min) and mandatory correction of coexisting hypomagnesemia.

Acute adrenal crisis presents with refractory distributive shock, high fever, abdominal pain, hyponatremia, hyperkalemia (in primary deficiency), and hypoglycemia; clinicians must never delay therapy for diagnostic testing—immediately draw baseline cortisol and ACTH, then administer IV Hydrocortisone 100 mg bolus every 8 hours and rapid resuscitation with IV 5% Dextrose in 0.9% Normal Saline.

Last updated: September 2026

Hypercalcemic Crisis: Pathophysiology & Clinical Presentation

Calcium homeostasis is tightly regulated within a narrow physiologic range (normal total serum calcium: 8.5 to 10.5 mg/dL; ionized calcium: 1.15 to 1.35 mmol/L) through the coordinated actions of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D (calcitriol), and calcitonin on bone, kidneys, and the gastrointestinal tract. Approximately 40% to 45% of circulating calcium is bound to plasma proteins (primarily albumin), 10% is complexed with anions (phosphate, citrate), and 45% to 50% circulates as physiologically active, free ionized calcium.

Corrected Calcium Formula

Because routine chemistry panels measure total calcium, hypoalbuminemia falsely depresses the measured value:

Corrected Total Calcium (mg/dL) = Measured Total Calcium + 0.8 x (4.0 - Serum Albumin [g/dL])

Clinical Caveat : In critically ill patients, cirrhotics, or patients with acid-base disturbances, the formula is inaccurate; direct measurement of ionized calcium is the clinical gold standard.

• Severity Classification
• Mild Hypercalcemia : Total calcium 10.5 to 11.9 mg/dL (often asymptomatic or mild constipation)
• Moderate Hypercalcemia : Total calcium 12.0 to 13.9 mg/dL (fatigue, polyuria, anorexia)

Hypercalcemic Crisis (Severe) : Total calcium >=14.0 mg/dL (or ionized calcium >3.0 mmol/L). Represents an acute medical emergency characterized by life-threatening dehydration, renal failure, cardiac dysrhythmias, and progressive encephalopathy.

Clinical Manifestations: "Stones, Bones, Abdominal Groans, Thrones & Psychiatric Overtones"

Renal ("Stones & Thrones") :

Nephrogenic Diabetes Insipidus (NDI) : Hypercalcemia activates calcium-sensing receptors (CaSR) in the basolateral membrane of the collecting duct, inducing endocytosis and downregulation of aquaporin-2 water channels . This causes severe polyuria, nocturia, and polydipsia refractory to ADH.

Calcium additionally interferes with the countercurrent multiplier mechanism in the thick ascending limb of Henle.

Nephrolithiasis (calcium oxalate/phosphate stones), nephrocalcinosis, and pre-renal azotemia from profound fluid deficits (typically 3 to 5 liters ).

Gastrointestinal ("Abdominal Groans") :

Severe constipation, nausea, intractable vomiting, and anorexia.

Acute Pancreatitis : Elevated calcium activates intra-acinar trypsinogen into active trypsin, precipitating autodigestive pancreatic necrosis.

Peptic Ulcer Disease : Calcium directly stimulates gastrin hypersecretion from G cells and gastric acid production by parietal cells.

Neurological ("Psychiatric Overtones") :

Progressive neuromuscular depression: muscle weakness, hyporeflexia, cognitive slowing, anxiety, depression, acute delirium, psychosis, stupor, and coma.

Cardiovascular Manifestations :

Shortened QT interval on ECG (accelerated phase 2 plateau of the myocyte action potential);

Cardiac arrhythmias, increased vascular tone (hypertension), and heightened vulnerability to digitalis toxicity.

Etiology: Primary Hyperparathyroidism versus Malignancy

Together, primary hyperparathyroidism and malignancy account for >90% of all hypercalcemia cases : DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA

• PRIMARY HYPERPARATHYROIDISM HYPERCALCEMIA OF MALIGNANCY
• (Most common outpatient, 90% of clinic) (Most common inpatient, 80% of ICU)
• ┌────────────────────────────────────┐ ┌────────────────────────────────────┐
• │ • Intact PTH: ELEVATED or │ │ • Intact PTH: SUPPRESSED (<10 pg) │
• │ inappropriately normal │ │ • Rapid onset, severe (Ca >14 mg) │
• │ • Serum Phosphate: Low or normal │ │ • 3 Mechanisms: │
• │ • 1,25-(OH)2D: Normal or elevated │ │ 1. PTHrP secretion (80%) │
• │ • Solitary adenoma (85%), │ │ Squamous cell (lung/head/neck)│
• │ hyperplasia (15%), carcinoma (<1%)│ │ 2. Osteolytic metastases (20%) │
• │ • Indolent, mild-to-moderate │ │ Multiple myeloma, breast │
• │ • Treatment: Parathyroidectomy │ │ 3. Calcitriol excess (1%) │
• │ │ │ Lymphomas, Sarcoidosis │
• └────────────────────────────────────┘ └────────────────────────────────────┘

Humoral Hypercalcemia of Malignancy (HHM - 80% of cancer cases) :

Tumors secrete Parathyroid Hormone-Related Protein (PTHrP) , which binds to and activates common PTH1 receptors in bone and kidney.

Stimulates osteoclast resorption and renal calcium retention without stimulating renal 1-alpha-hydroxylase (thus calcitriol is low/normal).

Classic malignancies: Squamous cell carcinomas (lung, head and neck, esophagus), renal cell carcinoma, ovarian carcinoma.

Local Osteolytic Hypercalcemia (20% of cancer cases) :

Extensive skeletal metastases or marrow infiltration: Multiple myeloma , metastatic breast cancer, non-small cell lung cancer.

Malignant cells release local cytokines (RANKL, IL-1, IL-6, TNF-alpha) driving profound osteoclast-mediated bone destruction.

1,25-Dihydroxyvitamin D (Calcitriol) Overproduction (1% of cancer cases) :

Autonomous extra-renal 1-alpha-hydroxylase expression in tumor-associated macrophages.

Seen in Hodgkin and non-Hodgkin lymphomas and non-malignant granulomatous disorders ( Sarcoidosis , tuberculosis, berylliosis).

Hypercalcemia Emergency Pharmacotherapy Protocol STEPWISE HYPERCALCEMIA MANAGEMENT

• STEP 1: SALINE RESUSCITATION STEP 2: CALCITONIN BRIDGE
• ┌──────────────────────────────┐ ┌──────────────────────────────┐
• │ • 0.9% Normal Saline IV │ │ • Salmon Calcitonin │
• │ • 1000-2000 mL over 1-2 h │ ──► │ 4-8 IU/kg SC/IM q12h │
• │ • Maintenance: 200-500 mL/h │ │ • Onset: 2-4 hours │
• │ • Enhances renal calciuresis │ │ • Tachyphylaxis in 48 hours │
• │ • NO FUROSEMIDE acutely! │ │ • Bridges until bisphosphonate│
• └──────────────────────────────┘ └──────────────────────────────┘
• │
• ▼
• STEP 3: BISPHOSPHONATE STEP 4: SPECIALTY AGENTS
• ┌──────────────────────────────┐ ┌──────────────────────────────┐
• │ • Zoledronic Acid 4 mg IV │ │ • Denosumab (RANKL Ab) 120mg │
• │ infused over 15 minutes │ │ (If GFR <30 mL/min or │
• │ • Inhibits osteoclasts │ ──► │ refractory to zoledronate)│
• │ • Onset: 2-4 days │ │ • Corticosteroids (Prednisone│
• │ • Nadir: 4-7 days │ │ 40-60mg for lymphoma/sarco)│
• │ • Avoid if GFR <30 mL/min │ │ • Hemodialysis (if Ca >18) │
• └──────────────────────────────┘ └──────────────────────────────┘
• Step 1: Aggressive Volume Resuscitation (Isotonic Normal Saline)

Rationale : Patients in hypercalcemic crisis are universally and profoundly dehydrated (3 to 5 L fluid deficit) secondary to nephrogenic diabetes insipidus, vomiting, and decreased intake.

Administration Protocol :

Initial Bolus : 0.9% Normal Saline at 1000 to 2000 mL IV over the first 1 to 2 hours.

Maintenance Infusion : Continue normal saline at 200 to 500 mL/h , titrating to maintain a robust urine output of 100 to 150 mL/h .

Mechanism : Normal saline expands intravascular volume, restores GFR, and increases distal sodium and fluid delivery. In the thick ascending limb of Henle, calcium reabsorption is passively linked to sodium reabsorption; inducing natriuresis directly promotes passive renal calcium excretion .

Expected Effect : Lowers serum calcium by 1.5 to 3.0 mg/dL within 24 to 48 hours.

The Critical Loop Diuretic Warning :

Furosemide is CONTRAINDICATED in the initial management of hypercalcemic crisis.

Administering a loop diuretic to a volume-depleted hypercalcemic patient worsens hypovolemia, decreases GFR, and paradoxically elevates serum calcium.

Loop diuretics are indicated strictly after the patient is completely euvolemic , and only if signs of volume overload (pulmonary edema, heart failure) emerge.

Step 2: Calcitonin (The Immediate Bridge)

Dose : Salmon Calcitonin 4 to 8 IU/kg SC or IM every 12 hours .

Mechanism : Binds calcitonin receptors on osteoclasts, acutely inhibiting bone resorption; also promotes renal calcium clearance.

Pharmacodynamics :

Rapid onset within 2 to 4 hours ; lowers serum calcium by 1 to 2 mg/dL .

Crucial Limitation : Tachyphylaxis develops within 48 hours due to rapid downregulation and internalization of calcitonin receptors on osteoclast surfaces. Calcitonin serves exclusively as a rapid, temporary bridge while awaiting the onset of bisphosphonates.

Step 3: Intravenous Bisphosphonates (Definitive Long-Acting Therapy)

Agent of Choice : Zoledronic Acid 4 mg IV infused over at least 15 minutes (superior efficacy and longer duration of action compared to pamidronate 60-90 mg IV infused over 2-4 hours).

Mechanism : Pyrophosphate analog that binds hydroxyapatite crystals in mineralized bone, entering osteoclasts and inhibiting farnesyl pyrophosphate synthase, inducing osteoclast apoptosis and blocking osteolytic bone resorption.

Pharmacodynamics :

Onset of action is 2 to 4 days ; nadir of serum calcium occurs at 4 to 7 days ; duration of normocalcemia lasts 2 to 4 weeks.

Safety in Renal Impairment :

Bisphosphonates are excreted renally and can cause acute tubular necrosis. Zoledronic acid requires caution and dose adjustment in chronic kidney disease and is generally contraindicated when serum creatinine is >4.5 mg/dL or GFR is <30 mL/min .

Step 4: Denosumab (RANKL Inhibitor)

Dose : Denosumab 120 mg subcutaneously (with additional 120 mg loading doses on days 8 and 15 in refractory malignancy).

Mechanism : Fully human monoclonal antibody that binds and neutralizes RANKL (Receptor Activator of Nuclear Factor-kB Ligand) , preventing RANKL from binding to its receptor RANK on osteoclast precursors. This completely arrests osteoclast proliferation, differentiation, and survival.

Clinical Indications :

Severe Renal Impairment : Denosumab is not cleared by the kidneys and can be safely administered in patients with GFR <30 mL/min or on hemodialysis where bisphosphonates are contraindicated;

Bisphosphonate-Refractory Hypercalcemia of Malignancy .

Step 5: Corticosteroids

Indication : Hypercalcemia mediated by 1,25-dihydroxyvitamin D (calcitriol) excess (Hodgkin and non-Hodgkin lymphoma, sarcoidosis, tuberculosis, berylliosis).

Dosing : Prednisone 40 to 60 mg orally daily (or IV Hydrocortisone 100 mg q8h).

Mechanism : Inhibits 1-alpha-hydroxylase activity in macrophages and downregulates intestinal calcium absorption. Onset of action is 2 to 5 days.

Step 6: Emergent Hemodialysis

Reserved for life-threatening hypercalcemia (calcium >18 to 20 mg/dL ), hypercalcemia accompanied by acute oliguric renal failure, intractable pulmonary edema, or severe neurologic coma. Hemodialysis using a zero- or low-calcium dialysate bath is the most rapid clearance modality.

• Severe Acute Hypocalcemia: Diagnosis, Signs & IV Calcium Replacement
• Severity Classification
• Normal Total Calcium : 8.5 to 10.5 mg/dL; Ionized Calcium : 1.15 to 1.35 mmol/L

Severe / Critical Hypocalcemia : Ionized Calcium <1.1 mmol/L (critical emergency when <0.9 mmol/L), or total calcium <7.0 mg/dL.

Neuromuscular Irritability Signs

Hypocalcemia decreases the threshold potential of excitable neurons and myocytes, causing spontaneous depolarization and repetitive axonal firing:

Paresthesias : Early symptoms include circumoral numbness, tingling in the fingertips and toes.

Chvostek Sign : Tapping the facial nerve trunk anterior to the external auditory meatus produces brisk ipsilateral twitching of the facial muscles (twitch of the lip, ala nasi, or orbicularis oculi). Positive in ~70% of hypocalcemic patients, but also present in ~10% of healthy individuals.

Trousseau Sign : Inflating a sphygmomanometer blood pressure cuff to 20 mmHg above systolic blood pressure for 3 minutes produces painful carpopedal spasm (flexion of the wrist and MCP joints, extension of the IP joints, and adduction of the thumb ["obstetrician's hand"]). Trousseau sign is 94% sensitive and highly specific for latent tetany (far more reliable than Chvostek sign).

Severe Manifestations : Laryngeal stridor, laryngospasm, bronchospasm, generalized tonic-clonic seizures, impaired cardiac contractility (congestive heart failure), and marked QTc interval prolongation predisposing to ventricular arrhythmias.

Acute Intravenous Treatment Protocol

Agent of Choice: Intravenous Calcium Gluconate 10% :

Administer 1 to 2 grams (10 to 20 mL of 10% solution) diluted in 50 to 100 mL of 5% Dextrose in Water (D5W) infused IV over 10 to 20 minutes with continuous cardiac telemetry monitoring.

Why Calcium Gluconate over Calcium Chloride? Calcium chloride contains three times more elemental calcium, but carries an extreme risk of severe chemical thrombophlebitis and devastating full-thickness skin necrosis if extravasation into subcutaneous tissues occurs. Calcium gluconate is much safer for peripheral venous administration.

Continuous Infusion : If hypocalcemia and tetany recur after bolus therapy, initiate a continuous infusion: add 100 mL of 10% calcium gluconate (10 ampules, ~900 mg elemental calcium) to 1000 mL D5W, infused at 50 mL/h (0.5 to 1.5 mg/kg/h) .

The Mandatory Magnesium Rule : Always check and replete serum magnesium. Hypomagnesemia suppresses PTH secretion and causes end-organ PTH resistance. Hypocalcemia is refractory to calcium repletion until hypomagnesemia is corrected.

Acute Adrenal Crisis: Etiology, Refractory Shock & Resuscitation

Acute adrenal crisis is a catastrophic, life-threatening endocrine emergency resulting from acute absolute or relative insufficiency of adrenal corticosteroids. PRIMARY VS. SECONDARY ADRENAL INSUFFICIENCY

• PRIMARY ADRENAL INSUFFICIENCY SECONDARY / TERTIARY INSUFFICIENCY
• (Addison Disease) (Pituitary / Steroid Cessation)
• ┌───────────────────────────────────┐ ┌───────────────────────────────────┐
• │ • Entire Adrenal Cortex Destroyed │ │ • Pituitary ACTH Deficiency or │
• │ • Cortisol: DEFICIENT │ │ Abrupt Exogenous Steroid Stop │
• │ • Aldosterone: DEFICIENT │ │ • Cortisol: DEFICIENT │
• │ • Etiologies: Autoimmune (80%), │ │ • Aldosterone: PRESERVED (RAAS │
• │ Waterhouse-Friderichsen (men- │ │ operates independently of ACTH) │
• │ ingococcemia), Bilateral bleed │ │ • Etiologies: Abrupt steroid stop │
• │ • Hallmarks: Hyponatremia PLUS │ │ (most common), Sheehan, apoplexy│
• │ HYPERKALEMIA & hyperpigmentation│ │ • Hallmarks: Hyponatremia WITHOUT │
• └───────────────────────────────────┘ │ hyperkalemia; normal skin │
• └───────────────────────────────────┘
• Etiology & Pathophysiology

Primary Adrenal Insufficiency (Addison Disease) :

Destruction of all three zones of the adrenal cortex (zona glomerulosa, fasciculata, reticularis).

Results in combined glucocorticoid (cortisol) AND mineralocorticoid (aldosterone) deficiency .

Causes: Autoimmune adrenalitis (80% in developed countries), tuberculosis, fungal infections, bilateral adrenal metastases, and bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome complicating Neisseria meningitidis septicemia, antiphospholipid syndrome, or heparin-induced thrombocytopenia).

Secondary / Tertiary Adrenal Insufficiency :

Failure of pituitary ACTH secretion (pituitary adenoma, surgery, radiation, Sheehan syndrome, pituitary apoplexy) or hypothalamic CRH suppression.

Most Common Cause : Abrupt cessation of chronic exogenous corticosteroid therapy (doses equivalent to >=20 mg prednisone daily for >3 weeks induce prolonged hypothalamic-pituitary-adrenal [HPA] axis suppression that may take up to a year to recover).

Key Pathophysiologic Hallmark : Mineralocorticoid secretion (aldosterone) is PRESERVED because aldosterone is regulated by the renin-angiotensin-aldosterone system (RAAS) and extracellular potassium, not pituitary ACTH.

Clinical Presentation: The Distributive Shock State

Refractory Distributive Shock : Profound vascular collapse and hypotension completely unresponsive to vigorous volume resuscitation and high-dose vasopressors. Cortisol is an essential permissive hormone required for vascular smooth muscle alpha-1 adrenergic receptor synthesis and responsiveness; without cortisol, catecholamines cannot maintain vascular tone.

Acute Abdomen Presentation : Severe, unremitting abdominal pain, flank pain, nausea, intractable vomiting, and abdominal guarding—frequently misdiagnosed as an acute surgical abdomen or perforated ulcer.

High Unexplained Fever : Cortisol deficiency releases uninhibited pyrogenic cytokines (IL-1, IL-6, TNF-alpha).

Altered Mental Status : Confusion, apathy, extreme lethargy, delirium, or coma.

Diagnostic Laboratory Pattern

Laboratory Parameter Primary Adrenal Crisis Secondary / Tertiary Adrenal Crisis

Serum Sodium Low (Hyponatremia) (aldosterone & cortisol loss) Low (Hyponatremia) (dilutional via uninhibited ADH)

• Serum Potassium HIGH (Hyperkalemia) (loss of aldosterone) NORMAL (aldosterone preserved by RAAS)
• Blood Glucose Low (Hypoglycemia) Low (Hypoglycemia)
• Acid-Base Status Non-anion gap metabolic acidosis (loss of H+ excretion) Normal acid-base status
• Cutaneous Exam Hyperpigmentation (high ACTH/MSH at palmar creases, scars) Pale, alabaster skin (low ACTH)
• Emergency Management Protocol: The "Never Delay" Rule

Caution

Cardinal Board Rule : If acute adrenal crisis is suspected, NEVER delay life-saving corticosteroid replacement to perform diagnostic confirmation! Untreated acute adrenal crisis carries a mortality approaching 100%.

Diagnostic Blood Draw :

Rapidly draw blood for baseline serum cortisol, plasma ACTH, and comprehensive metabolic panel; immediately initiate therapy without waiting for results.

Glucocorticoid Resuscitation :

First-Line Agent: Intravenous Hydrocortisone 100 mg bolus immediately , followed by 100 mg IV every 8 hours (or 200 mg continuous IV infusion over 24 hours).

Why Hydrocortisone? At stress doses (>=100 mg/day), hydrocortisone provides maximum glucocorticoid activity AND sufficient cross-over mineralocorticoid receptor activity to restore renal sodium conservation, rendering additional fludrocortisone unnecessary during acute resuscitation.

Alternative when Cosyntropin Testing is Planned : If a cosyntropin (synthetic ACTH 250 mcg) stimulation test is being performed concurrently, administer IV Dexamethasone 4 mg bolus . Dexamethasone does not cross-react with serum cortisol radioimmunoassays, permitting accurate measurement of endogenous cortisol levels. (Note: Dexamethasone has zero mineralocorticoid activity, requiring vigilant saline resuscitation).

Volume and Dextrose Resuscitation :

Administer IV 5% Dextrose in 0.9% Normal Saline (D5NS) : Initial bolus of 1000 mL in the first hour , followed by maintenance infusion at 250 to 500 mL/h .

D5NS simultaneously accomplishes three life-saving goals: restores depleted intravascular volume, replaces total body sodium deficits, and corrects life-threatening hypoglycemia.

Maintenance Transition :

Once the patient is stabilized, hydrocortisone is tapered over 48 to 72 hours to oral maintenance doses (15-20 mg morning, 5-10 mg evening).

In primary adrenal insufficiency, oral Fludrocortisone (0.05 to 0.2 mg PO daily) is added only after IV hydrocortisone is tapered below 50 mg/day.

Loading diagram... Emergency Protocols for Hypercalcemic Crisis and Acute Adrenal Crisis